Related Experiment Video

Updated: Jun 20, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

Sedating the child with congenital heart disease

Laura K Diaz1, Lisa Jones

  • 1Division of Cardiothoracic Anesthesiology, Department of Anesthesiology and Critical Care Medicine, The Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA. diazl@email.chop.edu

Anesthesiology Clinics
|August 26, 2009
PubMed

Insights

Pediatric sedation for procedures outside the operating room is increasing, especially for children with congenital heart disease. Enhanced safety guidelines and vigilance are crucial for these complex cases.

Area of Science:

  • Pediatric Anesthesiology and Critical Care
  • Cardiology and Pulmonary Medicine

Background:

  • The number of pediatric patients requiring sedation for non-operating room procedures is rising annually.
  • An increasing number of patients with congenital heart disease (CHD) are surviving into adulthood, often with residual conditions.
  • Sedation for pediatric patients with complex medical histories, such as CHD or pulmonary hypertension, presents unique challenges.

Purpose of the Study:

  • To highlight the growing need for safe sedation practices in pediatric patients undergoing procedures outside the operating room.
  • To emphasize the specific challenges and heightened vigilance required for sedating pediatric patients with congenital heart disease or pulmonary hypertension.
  • To underscore the role of organizations like the Society for Pediatric Sedation in promoting safe care and practitioner education.

Main Methods:

  • Review of current trends in pediatric procedural sedation.
  • Analysis of safety considerations for pediatric patients with congenital heart disease and pulmonary hypertension.
  • Discussion of the impact of remote procedural locations on sedation safety.

Main Results:

  • Significant advancements have been made in developing guidelines to prevent adverse events during pediatric sedation.
  • The Society for Pediatric Sedation and the Pediatric Sedation Research Consortium are key resources for education and safe practice.
  • Patients with congenital heart disease or pulmonary hypertension represent a particularly vulnerable group requiring specialized sedation protocols.

Conclusions:

  • Continuous development of safety guidelines is essential to manage the increasing number of pediatric sedation cases.
  • Specialized care and heightened vigilance are paramount for the safe sedation of pediatric patients with congenital heart disease or pulmonary hypertension, particularly in remote settings.
  • Collaboration and education through professional societies are vital for ensuring optimal outcomes in pediatric procedural sedation.

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Drug Delivery: Enteral Route01:18

Drug Delivery: Enteral Route

The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
Drugs in...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...